The Relationship among Pore-Size Ratings, Bubble Points, and Porosity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relationship among Pore-Size Ratings, Bubble Points, and Porosity


Pharmaceutical Technology


Pore-size ratings and validation

Until rather recently it was believed that the sterilization of fluids could be achieved by their filtration through a "sterilizing" membrane whose proper and pertinent identity was confirmed by its pore-size rating, which was itself determined by bubble-point measurement. This belief arose from the membrane's successfully withstanding a microbiological challenge of 1 107 cfu of B. diminuta per square centimeter of filter surface. On this basis, the membrane, in accord with FDAs definition, was considered a "sterilizing filter."

Contrary to common belief, B. diminuta was not selected to be the model organism because it was thought to be the smallest microbe—smaller organisms were known for decades (30). Rather, it was chosen as likely to be the smallest organism that might commonly be encountered in nonsterile pharmaceutical preparations. Therefore, its filtrative removal was considered as indicating with a high probability that the membrane used was a sterilizing filter. Using this type filter, identified by its bubble point, was assumed, with this caveat, to ensure a sterile effluent.

Over time, it became evident that positive conclusions based on pore-size ratings were subject to modification by the physicochemical specificity of the organism-suspending fluid, by the individuality of the organism type in its size-changing response to the fluid, in the possible change in pore size induced by the fluid, and by the adsorptive qualities of the filter resulting from its particular polymeric composition. All of these factors are influenced by the filtration conditions in their numerous varieties, but especially by the transmembrane pressure.

A filter may not sterilize the same preparation under different filtration conditions, especially under dissimilar differential pressures (31). A given membrane may or may not retain a particular organism type suspended in a different drug vehicle (3, 31). The organism type need not remain constant in size but may alter in response to its suspending fluid (32–34). The effect of the vehicle upon the polymeric membrane may cause a change in its pore sizes (24). What had once seemed simple is now recognized as being quite complex. Pore-size ratings alone are not sufficient to ensure the validation of a sterilizing filtration.

Given the above, it is surprising that The European Medicines Agency (EMEA) has stipulated certain requirements for a bioburden confronting the sterilizing filter. Its 1996 Notes for Guidance states, "In most situations NFT 10 cfu/100 mL will be acceptable depending on the volume to be filtered in relation to the diameter of the filter. If this requirement is not met, it is necessary to use a prefiltration through a bacteria-retaining filter to obtain a sufficiently low bioburden" (35). In recommending the use of a bioburden-reducing filter when the level of 10 cfu/100 mL is exceeded, the EMEA guideline states, "The type of bacteria-retentive filter and its pore size should also be described in the application. Pore sizes of 0.22 μm are acceptable without further justification" (emphasis added). It would seem that validation by pore size is still acceptable to the EMEA.

Organism quantitation

Conclusions cannot be made regarding the sterile filtration of microorganisms unless methods of quantifying them by culturing and counting are available. Organisms such as the L-forms, nanobacteria, and "viable but nonculturable" entities may not be amenable to such analyses. Concerns about their presence may be justified but without the means to cultivate and count them, it is impossible to attest to their complete absence. It follows that a sterilizing filter can be judged only by its performance in the removal of identifiable and culturable organisms known to be present in the drug preparation (36).

Bubble points and "the largest pores"

An alternative approach focuses on measuring the set of "largest pores" of a filter. These are the least resistant to fluid flow. They, if any, would be the most likely to permit organism passage. The measurement is of the pores' constricted diameters rather than of their lengths. It is at these choke points that the size of a particle just large enough to be retained is defined. The pore diameter varies along the length of the pore passageway and differs among the various pores of the filter; hence, pore-size distributions characterize the microporous membranes.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here